ArticlePDF Available

Calciphylaxis

Authors:
  • Nanjappa Hospital
INDIAN JOURNAL OF KIDNEY DISEASES
38
Anupama Y J
Address for correspondence:
Dr Anupama Y J, Senior Consultant Nephrologist
Nanjappa Hospitals, Shivamogga 577201, Karnataka
E: anupamayj@ gmail.com
IMAGES IN NEPHROLOGY
Calciphylaxis
Figure 1: Clinical photograph of the Skin lesions
Downloaded from http://journals.lww.com/ijkd by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 06/06/2023
Volume-1, Issue-1 Jan-March 2022 IJKD 39
A 55-year old gentleman with diabetic chronic
kidney disease on regular haemodialysis for the
past three years, sought advice for painful skin
lesions on the left leg. There was no history of fever,
trauma or insect bite. His other comorbidities were
obesity, ischemic heart disease, hypertension,
HCV seropositive status and left subclavian
vein stenosis with severe venous hypertension.
His medications included nifedipine, clonidine,
sodium bicarbonate, periodic erythropoietin and
iron sucrose injections. On evaluation, he had a
2x4 cm necrotic ulcer covered with eschar over
the left leg two inches above the lateral malleolus
and two smaller necrotic areas 0.5x0.5 cm above
the medial malleolus (Figure 1). Dorsalis pedis
and posterior tibial arterial pulsations were not
felt in both legs. His lab results were as follows:
Haemoglobin-7.4 g/dl, serum creatinine-10.5mg/
dl, calcium-10.5 mg/dl, phosphorus - 4.1 mg/
dl (Ca*P product 41.1mg2 / dl2), albumin - 4.1 g/
dl, alkaline phosphatase-163 IU/l, parathyroid
hormone -276.8 pg/ml(normal-10-65 pg/ml).
X-ray of the left foot showed extensive calcification
of the blood vessels. Histopathologic examination
of skin biopsy revealed extensive calcification in
the subcutaneous tissue with calcific plugs in the
Figure 2: Skin biopsy of the lesion demonstrating calciphylaxis(HE, 40x)
1. Stratified squamous epithelium
2. Calcification in the subcutis
3. Calcification in the blood vessels
4. Calcification of the walls along with calcific obliteration of the lumen
www.winindia.org
Downloaded from http://journals.lww.com/ijkd by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 06/06/2023
INDIAN JOURNAL OF KIDNEY DISEASES
40
dermal vessels confirming calciphylaxis (Figure
2). He was treated with intensification of dialysis
against low calcium concentrates, cinacalcet and
antibiotics. Sodium thiosulfate was not available
and not given. The lesions worsened despite
these measures. He succumbed to intractable
sepsis ten weeks later.
Calciphylaxis or calcific uraemic
arteriolopathy(CUA) is a chronic progressive
syndrome of arteriolar media calcification,
thrombotic ischemia, and necrotic ulceration.1
It is mostly seen in patients with advanced
chronic kidney disease on haemodialysis. It may
rarely be seen in renal transplant recipients with
functioning kidneys.2,3 Few cases are reported
even in non-uraemic settings such as alcoholic
liver disease, connective tissue disease and
malignancies.3 The pathogenesis is unclear.
Disturbances in calcium-phosphorus metabolism
are mostly implicated. Hyperparathyroidism,
increased serum phosphorus, increased calcium
x phosphorus product>70 mg2/dl 2 , female sex,
obesity, diabetes, vitamin D therapy and warfarin
use are some of the factors associated with
calciphylaxis.1,4 Lesions start with tender red areas
developing into indurated plaques or nodules.
Patients may subsequently develop an eschar
followed by frank ulceration, gangrene or sepsis.
Proximal pattern of involvement with lesions
abdomen, thigh and buttocks carries a worse
prognosis.5 Rarely, penis, breasts and ear lobules
may become necrotic. The treatment is not well-
defined. Parathyroidectomy, oral calcimimetics,
sodium thiosulfate are some of the measures
that have been employed with variable success.
Aggressive wound debridement has been
advocated and hyperbaric oxygen may be useful
in healing of ulcers.5,6 The condition is associated
with significant morbidity and mortality. 80% of
the affected patients die of sepsis or organ failure,
usually within a year.1 Our patient was obese and
diabetic, but parathyroid hormone levels were
within acceptable range for the level of kidney
function. His calcium phosphorus product was
also within the recommended range for dialysis
patients. The cause for the lesions was not clear.
High index of suspicion in patients with CKD is
necessary for early diagnosis and limitation of
morbidity.
References:
1. Wollina U. Update on cutaneous calciphylaxis.
Indian J Dermatol 2013;58:87-92
2. Urmila A, Kumar R, Rao V. Secondary
Subcutaneous Rhizopus Infection in a
Posttransplant Recipient with Calcific Uremic
Arteriolopathy. Case Reports in Infectious
Diseases, vol. 2020, Article ID 8695204.
https://doi.org/10.1155/2020/8695204
3. Nigwekar SU, Wolf M, Sterns RH, Hix
JK.Calciphylaxis from nonuremic causes: a
systematic review.Clin J Am Soc Nephrol.
2008 Jul; 3(4):1139-43
4. Nigwekar SU, Kroshinksy D, Nazarian RM, et
al. Calciphylaxis: Risk Factors, Diagnosis, and
Treatment. Am J Kidney Dis 2015;66(1):133-
146. doi:10.1053/j.ajkd.2015.01.034.
5. Brandenburg VM, Kramann R, Rothe H,
Kaesler N, Korbiel J, Specht P et al.Calcific
uraemic arteriolopathy (calciphylaxis): data
from a large nationwide registry.Nephrol Dial
Transplant. 2017 Jan 1;32(1):126-132.
6. Bhambri.A, Del Rosso JQ. Calciphylaxis. J
Clin Aesthet Dermatol. 2008;1(2):38-41
Anupama Y J : Calciphylaxis
Downloaded from http://journals.lww.com/ijkd by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 06/06/2023
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Calcific uremic arteriolopathy is a rare condition affecting chronic kidney disease (CKD) patients on long-term dialysis. The clinical manifestations include subcutaneous skin necrosis and ulcers secondary to calcification of the subcutaneous blood vessels. The necrotic tissue often becomes a nidus of infection. The prognosis is often poor. We present a case of a renal allograft recipient who developed a subcutaneous necrotic lesion which was subsequently infected by Rhizopus spp. The patient underwent surgical debridement and antifungal therapy. The infection resolved completely. Our case represents agrave underlying condition predisposing a rare and serious posttransplant infection. The outcome was favourable because of early identification and treatment of the infection.
Article
Full-text available
Calciphylaxis is a devastating disorder with a mortality rate of 80% due to sepsis and organ failure. Hallmarks of this rare disease are arteriolar media calcification, thrombotic cutaneous ischemia, and necrotic ulcerations. Different mechanisms of vascular calcification can lead to calciphylaxis. Early diagnosis by deep cutaneous ulcer biopsy is most important for prognosis. Here, dermatologists play a significant role although treatment usually needs an interdisciplinary approach. Surgical procedures had been the cornerstone of treatment in the past including parathyroidectomy, but recently new medical treatments emerged aiming to normalize disturbances of minerals to reduce the serum concentration of sodium phosphate and to prevent precipitation and calcification. Multimodal therapy is warranted but only aggressive surgical debridement of cutaneous ulcers has shown significant outcome improvement.
Article
Background Calcific uraemic arteriolopathy (CUA, calciphylaxis) is a rare disease predominantly in dialysis patients and associated with high mortality. Painful skin ulcerations and calcification of cutaneous arterioles characterize calciphylaxis. Methods We established an observational, Internet-based registry allowing online notification for all German CUA cases. The registry recorded data about patient characteristics, biochemistry and therapies. Blood samples were stored in a central biobank. Results Between 2006 and 2015, 253 CUA patients were recorded: median age 70 [interquartile range (IQR) 61–76] years, 60% females and 86% (n = 207) dialysis patients, translating into an estimated annual incidence rate of 0.04% in German dialysis patients. Fifty-two per cent received vitamin K antagonists (VKAs) prior to CUA. Skin lesions were localized in 71% on the legs or gluteal region. In dialysis CUA patients median total serum calcium was 2.20 (IQR 2.06–2.37) mmol/L, phosphorus 1.67 (IQR 1.35–2.03) mmol/L, intact parathyroid hormone 147 (IQR 72–276) pg/mL and fetuin-A 0.21 (IQR 0.16–0.26) g/L (normal range 0.35–0.95). Median sclerostin, osteoprotegerin, TRAP5b, bone-specific alkaline phosphatase and c-terminal FGF23 levels were all elevated. The most frequently recorded therapeutic procedures in dialysis CUA patients were as follows: wound debridement (29% of cases), stopping VKA (25%), lowering calcium supply (24%), sodium thiosulphate (22%), application of vitamin K (18%), increase of dialysis duration/frequency (17%) and stoping active vitamin D (16%). Conclusions Approximately 50% of CUA patients used VKA. Our data suggest that uncontrolled hyperparathyroidism is not the key determinant of calciphylaxis. Therapeutic strategies were heterogeneous. The experience of the German registry will help substantially to initiate a large-scale multinational CUA registry.
Article
Calciphylaxis is a rare but devastating condition that has continued to challenge the medical community since its early descriptions in the scientific literature many decades ago. It is predominantly seen in patients with chronic kidney failure treated with dialysis (uremic calciphylaxis) but is also described in patients with earlier stages of chronic kidney disease and with normal kidney function. In this review, we discuss the available medical literature regarding risk factors, diagnosis, and treatment of both uremic and nonuremic calciphylaxis. High-quality evidence for the evaluation and management of calciphylaxis is lacking at this time due to its rare incidence and poorly understood pathogenesis and the relative paucity of collaborative research efforts. We hereby provide a summary of recommendations developed by a multidisciplinary team for patients with calciphylaxis. Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Article
Calciphylaxis, or calcific uremic arteriolopathy, is a well-described entity in end-stage kidney disease and renal transplant patients; however, little systematic information is available on calciphylaxis from nonuremic causes. This systematic review was designed to characterize etiologies, clinical features, laboratory abnormalities, and prognosis of nonuremic calciphylaxis. A systematic review of literature for case reports and case series of nonuremic calciphylaxis was performed. Cases included met the operational definition of nonuremic calciphylaxis-histopathologic diagnosis of calciphylaxis in the absence of end-stage kidney disease, renal transplantation, or acute kidney injury requiring renal replacement therapy. We found 36 cases (75% women, 63% Caucasian, aged 15 to 82 yr) of nonuremic calciphylaxis. Primary hyperparathyroidism, malignancy, alcoholic liver disease, and connective tissue disease were the most common reported causes. Preceding corticosteroid use was reported for 61% patients. Protein C and S deficiencies were seen in 11% of patients. Skin lesions were morphologically similar to calcific uremic arteriolopathy. Mortality rate was 52%, with sepsis being the leading cause of death. Calciphylaxis should be considered while evaluating skin lesions in patients with predisposing conditions even in the absence of end-stage kidney disease and renal transplantation. Nonuremic calciphylaxis is reported most often in white women. Mineral abnormalities that are invoked as potential causes in calcific uremic arteriolopathy are often absent, suggesting that heterogeneous mechanisms may contribute to its pathogenesis. Nonuremic calciphylaxis is associated with high mortality, and there is no known effective treatment.
  • . A Bhambri
  • Del Rosso
  • J Q Calciphylaxis
Bhambri.A, Del Rosso JQ. Calciphylaxis. J Clin Aesthet Dermatol. 2008;1(2):38-41